Skip to main content

and
  1. Article

    Open Access

    Intravaginal lactic acid gel versus oral metronidazole for treating women with recurrent bacterial vaginosis: the VITA randomised controlled trial

    Bacterial vaginosis is a common and distressing condition for women. Short-term antibiotic treatment is usually clinically effective, but recurrence is common. We assessed the effectiveness of intravaginal lac...

    Jonathan D. C. Ross, Clare Brittain, Jocelyn Anstey Watkins, Joe Kai in BMC Women's Health (2023)

  2. Article

    Open Access

    The DEVA trial: protocol for a randomised controlled trial of dequalinium chloride versus usual care antibiotics for the treatment of bacterial vaginosis

    Bacterial vaginosis (BV) is the most common cause of vaginal discharge in women of reproductive age, and it is estimated that up to a third of women will experience it at some point in their lives. BV produces...

    Rebecca Haydock, Trish Hepburn, Jonathan Ross, Jane Daniels, Clare Brittain in Trials (2022)

  3. Article

    Open Access

    What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial

    The SINS trial (Controlled Clinical Trials ISRCTN48755084; Eudract No. 2004-004506-24) is a randomised controlled trial evaluating long term success of excisional surgery vs. imiquimod 5% cream for low risk no...

    Michela Tinelli, Mara Ozolins, Fiona Bath-Hextall, Hywel C Williams in BMC Dermatology (2012)

  4. Article

    Open Access

    The SINS trial: A randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma

    Basal cell carcinoma is the commonest human cancer. Despite increasing incidence it remains poorly researched. While not life threatening it can cause significant cosmetic disfigurement. Imiquimod, a cream whi...

    Mara Ozolins, Hywel C Williams, Sarah J Armstrong, Fiona J Bath-Hextall in Trials (2010)